Microbes and Muscle: Europe’s Peptide Bet

Ajinomoto Bio-Pharma and Olon team up to expand peptide manufacturing in Europe and strengthen supply resilience

2 Nov 2025

Europe’s peptide drug industry is set to expand its manufacturing base after Ajinomoto Bio-Pharma Services and Italian pharmaceutical group Olon agreed a strategic partnership to increase regional production capacity.

The alliance aims to strengthen Europe’s ability to manufacture therapeutic peptides, a fast-growing class of medicines used to treat conditions including metabolic disorders and cancer. Rising global demand for peptide-based therapies has increased pressure on manufacturers to secure reliable, large-scale supply.

Peptide production has historically been difficult to scale. Traditional chemical synthesis methods are often expensive and complex, particularly as newer therapies require higher volumes and more intricate molecular structures. For drug developers, manufacturing capacity is becoming a strategic concern alongside clinical development and regulatory approval.

Under the agreement, Ajinomoto Bio-Pharma will contribute its microbial production technology, which uses engineered microorganisms to produce peptides more efficiently than conventional chemical processes. Olon will provide fermentation infrastructure and active pharmaceutical ingredient manufacturing capacity at its European facilities.

The companies said the partnership is designed to broaden manufacturing networks, improve scalability for peptide and protein therapeutics, and strengthen supply chain resilience through diversified production. Executives have identified efficiency, sustainability and long-term capacity expansion as central objectives.

Industry observers say the deal reflects a wider shift in the contract development and manufacturing sector. Pharmaceutical groups are increasingly seeking early-stage manufacturing partnerships to reduce operational risk and secure dependable supply chains for complex treatments such as peptides and other biologically derived medicines.

As microbial production methods expand, regulatory compliance and quality oversight will remain critical. Maintaining consistency and meeting stringent safety standards will be essential as companies move from clinical-scale output to commercial volumes.

The long-term impact of the partnership will depend on execution and market demand. However, the agreement adds to efforts to strengthen Europe’s position in advanced pharmaceutical manufacturing at a time when supply security has become a strategic priority for the region.